Mirum Pharmaceuticals, Inc. announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical development, clinical operations, and safety programs for Mirum?s pipeline of programs addressing rare diseases. Dr. Quan was most recently Chief Medical Officer at Nuvig Therapeutics.

Prior to Nuvig, she served in the same role at Modis Therapeutics, a company focused on rare genetic diseases (acquired by Zogenix, Inc. and subsequently UCB). Before Modis, she held clinical development leadership positions at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics, ALZA Corporation (Johnson and Johnson), Genentech, and PathoGenesis. Dr. Quan received a BA in molecular biology at the University of California, Berkeley, and an MD at Stanford University School of Medicine.

She completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in pulmonary and critical care medicine at the University of Washington. In tandem with Dr. Quan?s appointment, Mirum announced the promotion of Peter Radovich to President and Chief Operating Officer. Mr. Radovich oversees commercial, corporate development and supply chain functions for Mirum.